接受新辅助化疗的乳腺癌患者心脏毒性与神经毒性的MRI特征:动态变化及相互关系
研究评估乳腺癌患者新辅助化疗前后心脏-脑MRI参数与认知功能,比较非癌症治疗相关心功能障碍(CTRCD)组67例与CTRCD组18例。CTRCD组心脏毒性因子及脑总体积、灰质体积、白质体积变化与非CTRCD组存在显著差异,且CTRCD组较低心脏毒性因子与较大的脑体积变化显著相关。结论提示CTRCD患者存在心脏功能、脑结构严重改变及心脏毒性与神经毒性相互关联的共病。
要点
- 乳腺癌新辅助化疗后CTRCD组心脏毒性因子为0.342±0.742,非CTRCD组为-1.349±0.704,组间差异显著(p<0.001)。
- CTRCD组脑总体积变化(ΔTBV)为-15.706±11.421,非CTRCD组为-0.613±10.377,组间差异显著(p<0.001)。
- CTRCD组较低心脏毒性因子与较高ΔTBV(β=-0.792,p<0.001)、ΔGMV(β=-0.752,p=0.001)、ΔWMV(β=-0.773,p<0.001)显著相关。
核心结论
- 研究发现乳腺癌CTRCD患者存在严重的心脏功能、脑结构改变及心脏毒性与神经毒性相互关联的共病。
研究设计与样本
- 研究评估乳腺癌患者新辅助化疗前后心脏-脑MRI参数及认知功能,采用配对t检验和Wilcoxon符号秩检验评估纵向变化及差值(Δ=新辅助化疗后-新辅助化疗前),行主成分分析提取心脏毒性因子(FAC),线性回归模型评估FAC与神经毒性的关系,FDR校正(p<0.05)。
诊断标准与关键数值
- CTRCD组心脏毒性因子为0.342±0.742,非CTRCD组为-1.349±0.704,组间差异显著(p<0.001)。
- CTRCD组ΔTBV为-15.706±11.421,非CTRCD组为-0.613±10.377,组间差异显著(p<0.001)。
- CTRCD组ΔGMV为14.439±14.232,非CTRCD组为-4.308±12.098,组间差异显著(p=0.004)。
- CTRCD组ΔWMV为-6.724±7.097,非CTRCD组为-0.928±7.958,组间差异显著(p=0.008)。
- CTRCD组较低FAC与较高ΔTBV(β=-0.792,p<0.001)、ΔGMV(β=-0.752,p=0.001)、ΔWMV(β=-0.773,p<0.001)显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To investigate the changes in cardiotoxicity and neurotoxicity characteristics in patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NAC) and their interrelationships.
MATERIALS AND METHODS: Pre- and post-NAC heart-brain MRI parameters and cognitive function were assessed. Paired t-tests and Wilcoxon signed-rank tests were used to assess longitudinal changes and the delta values (Δ = post-NAC - pre-NAC) in heart, brain, and cognition. Principal component analysis was performed to extract a cardiotoxicity factor (FAC), and linear regression models assessed the relationship between FAC and neurotoxicity, with FDR correction (p < 0.05).
RESULTS: Sixty-seven BC patients were in the non-cancer therapy-related cardiac dysfunction (CTRCD) group, and 18 patients were in the CTRCD group. Compared to non-CTRCD patients, CTRCD patients exhibited significant differences in the FAC (0.342 ± 0.742 vs. -1.349 ± 0.704, p < 0.001), as well as in neurotoxicity traits, including total brain volume (ΔTBV, -0.613 ± 10.377 vs. -15.706 ± 11.421, p < 0.001), gray matter volume (ΔGMV, -4.308 ± 12.098 vs. 14.439 ± 14.232, p = 0.004), and white matter volume (ΔWMV, -0.928 ± 7.958 vs. -6.724 ± 7.097, p = 0.008). In the CTRCD group, lower FAC was significantly associated with high ΔTBV (β = -0.792, p < 0.001), ΔGMV (β = -0.752, p = 0.001), and ΔWMV (β = -0.773, p < 0.001).
CONCLUSION: Our study found severe changes in heart function, brain structure, and the interrelated comorbidity of cardiotoxicity and neurotoxicity in BC patients with CTRCD.
引用
- Luo X, Liu D, Tan Y, et al. MRI Characteristics of Cardiotoxicity and Neurotoxicity in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy: Dynamic Changes and Interrelationships. Acad Radiol. 2026. PMID: 41951500. doi:10.1016/j.acra.2026.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。